Literature DB >> 18418391

Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function.

S H Francis1, G Z Morris, J D Corbin.   

Abstract

Cyclic guanosine monophosphate (cGMP) in penile vascular smooth muscle cells (VSMC) plays a key role in promoting penile erection. Phosphodiesterase-5 (PDE5) in VSMC breaks down cGMP to counter this effect. Sildenafil (Viagra), vardenafil (Levitra) and tadalafil (Cialis), treatments for erectile dysfunction, inhibit PDE5 action. Many men with erectile dysfunction have improved erectile function after plasma inhibitor concentration falls below therapeutic levels. Maximum effect plus onset and duration of action of inhibitor determines its efficacy. The rate and extent of cellular drug accumulation and efflux of drug from smooth muscle cells plus persistence of drug effects in these cell impact these parameters. We propose possible molecular mechanisms that could account for prolonged action of PDE5 inhibitors including (1) persistence of biochemical effects after inhibitor is cleared from cells, and (2) retention of drug in VSMC beyond plasma clearance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18418391     DOI: 10.1038/ijir.2008.4

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  16 in total

Review 1.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 2.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Authors:  Sharron H Francis; Jennifer L Busch; Jackie D Corbin; David Sibley
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

3.  PDE-5 and NOS II mRNA expression in menopausal women: a molecular biology study.

Authors:  Gianna Pace; Paola Palumbo; Gianfranca Miconi; Vania Silvestri; Maria Grazia Cifone; Carlo Vicentini
Journal:  World J Urol       Date:  2010-02-23       Impact factor: 4.226

4.  A substitution in cGMP-dependent protein kinase 1 associated with aortic disease induces an active conformation in the absence of cGMP.

Authors:  Matthew H Chan; Sahar Aminzai; Tingfei Hu; Amatya Taran; Sheng Li; Choel Kim; Renate B Pilz; Darren E Casteel
Journal:  J Biol Chem       Date:  2020-06-05       Impact factor: 5.157

5.  Distinct allostery induced in the cyclic GMP-binding, cyclic GMP-specific phosphodiesterase (PDE5) by cyclic GMP, sildenafil, and metal ions.

Authors:  Kabir H Biswas; Sandhya S Visweswariah
Journal:  J Biol Chem       Date:  2010-12-29       Impact factor: 5.157

Review 6.  Clinical and molecular genetics of the phosphodiesterases (PDEs).

Authors:  Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis
Journal:  Endocr Rev       Date:  2013-12-05       Impact factor: 19.871

Review 7.  A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy.

Authors:  Samuel L Washington; Alan W Shindel
Journal:  Drug Des Devel Ther       Date:  2010-09-07       Impact factor: 4.162

8.  Erectile properties of the Rho-kinase inhibitor SAR407899 in diabetic animals and human isolated corpora cavernosa.

Authors:  Fabio Guagnini; Mara Ferazzini; Marco Grasso; Salvatore Blanco; Tiziano Croci
Journal:  J Transl Med       Date:  2012-03-23       Impact factor: 5.531

Review 9.  Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications.

Authors:  C Corinaldesi; L Di Luigi; A Lenzi; C Crescioli
Journal:  J Endocrinol Invest       Date:  2015-06-28       Impact factor: 4.256

Review 10.  Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair.

Authors:  Eric P Knott; Mazen Assi; Sudheendra N R Rao; Mousumi Ghosh; Damien D Pearse
Journal:  Int J Mol Sci       Date:  2017-03-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.